LYEL
Lyell Immunopharma Inc
NASDAQ · Biotechnology
$22.71
+0.07 (+0.31%)
Open$22.65
Previous Close$22.64
Day High$23.73
Day Low$22.30
52W High$45.00
52W Low$7.65
Volume—
Avg Volume78.1K
Market Cap482.45M
P/E Ratio—
EPS$-22.21
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+23.1% upside
Current
$22.71
$22.71
Target
$27.95
$27.95
$18.45
$27.95 avg
$35.39
Key Financials
| FY 2026 | FY 2025 | FY 2025 | |
|---|---|---|---|
| Revenue | 99.8K | 558.1K | 112.33M |
| Net Income | -560,513,187 | -2,819,798,034 | -19,714,534 |
| Profit Margin | -562,295.1% | -534,180.3% | -17.6% |
| EBITDA | -567,160,420 | -3,011,751,811 | -21,929,970 |
| Free Cash Flow | — | — | -8,566,773 |
| Rev Growth | -82.1% | -82.1% | +21.9% |
| Debt/Equity | — | — | 0.62 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |